Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed and dated IRB-approved informed consent form (ICF).~2. Men or women between the ages of 18 and 60, inclusive.~3. Subjects in good health as determined by medical history, physical and focused neurological examinations, clinical laboratory studies, electrocardiograms (ECGs), vital signs, and Investigator's judgement.~4. Presence of bilaterally symmetrical GL of moderate to severe rating at maximum frown, as measured using FWS by both the Investigator and subject prior to study treatment.~5. Subjects with sufficient visual acuity without the use of eyeglasses (contact lens use acceptable) to accurately assess their facial wrinkles as determined by Investigator's judgement.~6. Women of child bearing potential must not be pregnant, lactating, or planning to become pregnant during the study.~7. Women of non-childbearing potential must be either postmenopausal (at least 12 consecutive months of amenorrhea) or surgically sterile (e.g., tubal ligation, hysterectomy, etc.).~8. Women of childbearing potential agreeing to use dual methods of contraception from the day of dosing until 3 months afterwards. Female subjects using oral contraception must have initiated treatment at least 2 months prior to the day of dosing.~9. Male subjects with partner(s) of childbearing potential agreeing to use dual methods of contraception from the day of dosing until 3 months afterwards, and to no sperm donation from day of dosing until 3 months afterwards.~10. Willing and able to complete protocol requirements and instructions, which include completion of all required visits.~Exclusion Criteria:~1. Any condition that precludes a subject's ability to comply with study requirements, including completion of the study visits or inability to read, understand, and/or self-assess GL severity using FWS.~2. Any uncontrolled systemic disease or other medical condition.~3. Any medical condition that may put the subject at increased risk with exposure to botulinum toxin of any serotype, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function.~4. Current or previous botulinum toxin treatment of any serotype.~5. Anticipated need for treatment with botulinum toxin of any serotype for any reason during the study (other than study treatment).~6. Known immunization or hypersensitivity to any botulinum toxin serotype.~7. Known allergy or sensitivity to any of the components of the study treatments, or any materials used in the study procedures.~8. Any of the following procedures or treatments occurring within the specified period prior to screening:~   * 3 months: Non-ablative resurfacing laser or light treatment, microdermabrasion, or superficial peels.~  * 6 months: Any facial cosmetic procedure with medium depth to deep facial chemical peels (e.g., trichloroacetic acid \[TCA\] and phenol), or mid facial or periorbital laser skin resurfacing.~  * 6 months: On topical retinoid therapy and/or topical hormone cream applied to the face, who have not been on a consistent dose regimen and are unable to maintain the same regimen for the study.~  * 12 months: Mid-facial or periorbital treatment with non-permanent soft tissue fillers.~  * 12 months: On oral retinoid therapy.~9. Prior periorbital surgery, facial lift (full face or mid face), brow lift, or related procedures (e.g., eyelid \[blepharoplasty\] and/or eyebrow surgery).~10. Prior mid face or periorbital treatment with permanent soft tissue fillers, synthetic implantation (e.g., Gore-Tex®), and/or autologous fat transplantation.~11. Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick sebaceous skin.~12. The inability to substantially lessen facial rhytides (fixed lines) even by physically spreading them apart, as determined by the Investigator.~13. Permanent make-up that would interfere with the assessment of facial wrinkles.~14. Subjects who, in the Investigator's opinion, are unable or unwilling to maintain their standardized skin care regimen throughout the study period.~15. Any eyebrow or eyelid ptosis at baseline as determined by the Investigator.~16. Infection or skin disorder at the injection sites.~17. History of facial nerve palsy.~18. Recent history (within 6 months of screening) of alcohol or drug abuse based on the Investigator's judgement.~19. Anticipated need for surgery or overnight hospitalization during the study. Current enrollment in an investigational drug or device study or participation in such a study within 30 days or 5 half-lives of the drug, whichever is longer, of entry into this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Intervention: Drug: Placebo~Single Injection of placebo into five (5) 0.1 mL IM injections into glabellar area.
- EB-001 Dose 1 (1X) (Type: ACTIVE_COMPARATOR): Intervention: Drug: EB-001~Single Injection of Low Dose of EB-001 into five (5) 0.1 mL IM Injections into glabellar area
- EB-001 Dose 2 (3X) (Type: ACTIVE_COMPARATOR): Intervention: Drug: EB-001, 3X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area
- EB-001 Dose 3 (9X) (Type: ACTIVE_COMPARATOR): Intervention: Drug: EB-001, 9X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area
- EB-001 Dose 4 (12X) (Type: ACTIVE_COMPARATOR): Intervention: Drug: EB-001, 12X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area
- EB-001 Dose 5 (16X) (Type: ACTIVE_COMPARATOR): Intervention: Drug: EB-001, 16X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area
- EB-001 Dose 6 (21X) (Type: ACTIVE_COMPARATOR): Intervention: Drug: EB-001, 21X Dose 1 Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area
- EB-001 Dose 7 (28X) (Type: ACTIVE_COMPARATOR): Intervention: Drug: EB-001, 28X Dose 1~Single Injection of Highest Dose of EB-001 into five (5) 0.1 mL IM Injections into glabellar area

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete